Pre-hospital environment bleeding: from history to future prospects

Bruno M. Pereira1,2,3,4, Alcir E. Dorigatti2, Luis Guilherme M.B. Calderon3, Mayara Negrão4, Guilherme Meirelles5, Juan C. Duchesne6

1Post Graduation and Research Division, Masters Program in Health Applied Sciences, Vassouras University, Vassouras, RJ, Brazil
2Grupo Surgical, Campinas, SP, Brazil
3Terzius Institute of Education, Campinas, SP, Brazil
4Campinas Holy House, Campinas, SP, Brazil
5Division of Trauma Surgery, Department of Surgery, UNICAMP, Campinas, SP, Brazil
6Department of Surgery Tulane, Norman McSwain Level I Trauma Center, New Orleans, Louisiana, USA

Abstract

While the blood was related to life since antiquity, scientific investigations on anatomy and physiology of the circulation system had to wait until the arrival of the 16th century. In trauma patients, hemorrhagic shock is the main risk factor for multiple organ dysfunction and consequent increased mortality. On the pre-hospital setting intravenous administration of crystalloid solution became the more common intervention during resuscitation of trauma patient due to many reasons although currently new discussions have blossomed on regards type of fluids and resuscitation. The object of this manuscript is to review the history of pre-hospital care bleeding management and to gather new perspectives for the future. Herein authors discuss several issues on bleeding control: 1. Current status and future possibilities on stop the bleeding in the pre-hospital setting – movements after the Hartford Consensus, use of topic homeostatic agents, tourniquets, REBOA and other radical interventions; 2. Damage control resuscitation in the pre-hospital environment – is massive transfusion protocol feasible at this setting? Tranexemic acid should be done? Possibilities that may improve survival and coagulopathy understanding; 3. Critical decision and decision making on stop the bleed; 4. Proposed flowchart on bleeding control.

The implementation of measures to stop acute bleeding in the pre-hospital setting is a well-known and well-founded measure. However, the provision of current evidence demonstrates that these measures go far beyond compression and elevation of the limb as was known in the past. The deep understanding of the mechanism of coagulopathy and the new adjuvant arsenal to control bleeding are essential for a better quality of pre-hospital medical care as well as lower mortality rates.

Key words: bleeding, pre-hospital care, trauma, resuscitation.
cussions have blossomed as regards type of fluids and resuscitation. Indeed, fluid replacement is now taken with caution, with different comprehension from what it was at the time of World Wars I & II, and the Wars of Korea and Vietnam. The updated understanding on fluid replacement led the IFA (International Fluid Academy) to suggest the rule of 4Ds for fluids: Drugs, Dose, Duration, De-escalation [6]. In the current concept, it is paramount to give the right fluid, at the right moment considering each patient population, risk factors and ongoing morbidity. It is also important to consider volume and fluid infusion rates based on pharmacokinetics, pharmacodynamics and toxicity. To date, the continuous infusion of fluids after the resuscitation phase may also be considered with caution. When the expected resuscitation target is reached, fluid infusion should be discontinued [6].

Crystalloids are electrolyte-enriched solutions and sodium is the main electrolyte contained in these solutions. This chemical element diffuses rapidly with water through the vascular endothelium and stays free in the extravascular and interstitial compartment. By the infusion of one liter of crystalloids, 75% of this volume spreads into the interstitial space; therefore only 25% maintains plasma volume expansion [7]. Due to its availability and relative safety, crystalloid solutions became the fluid of choice in the treatment of hemorrhagic shock during the 19th and early 20th centuries [8–10].

Over an historic perspective, during World War I resuscitation with crystalloids seemed not to be effective [11]. Plasma was then found to be a more effective volume expansion solution together with whole blood transfusion, which became the first option during that period of conflict [12]. During WWII, the goal was to keep systolic blood pressure higher than 85 mm Hg until the bleeding source was taken under control [13–15].

During the Vietnam War, crystalloid solutions returned to the scene as the field resuscitation first choice, based on studies indicating that resuscitation with Lactated Ringer was the best option when compared to whole blood when looking specifically for improvement of survival [16–20]. Later on, research demonstrated that an increasing crystalloid volume infusion was correlated with intestinal perfusion decrease, abdominal compartment syndrome, pulmonary and cardiac dysfunction and death [21–23].

In the same period new techniques of blood fractionation were developed dividing whole blood into units of red blood cells, plasma and platelets. In addition, even without a single study showing the effects of using fractionated blood in patients with hemorrhagic shock, this was the way of taking all indicated transfusions including outside the war field [24, 26]. Medical practice was becoming far away from whole blood transfusion by that period of time. This continued in the last three decades of the 20th century, when studies indicated that the use of Lactated Ringer and up to six unit of red blood cells could be used without causing coagulopathy. Other studies indeed pointed out that there was no indication for transfusion with plasma or platelets without laboratory coagulation [27, 28].

Carrico et al. in an important study affirmed that the use of two liters of crystalloids while waiting for blood transfusion was safe. This study was widely disseminated around the world by the American College of Surgeons through the Advanced Trauma Life Support program, encouraging thousands of doctors to perform an aggressive volume resuscitation for many years. Multicenter studies have never shown the benefit of using aggressive volume resuscitation whatsoever [30, 31]. In 1994 another study showed that the infusion of a major volume of fluid infusion before bleeding control was associated with worse prognosis [32]. Recent studies have indicated that when a patient sustains extensive tissue damage associated with severe hypotension, coagulation dysfunction rapidly occurs [33]. Several hypotheses justify this phenomenon, for instance: 1) aggressive fluid administration – to be responsible for whole blood and coagulation factors’ dilution and fibrinolysis, 2) release of plasminogen activating factor secondary to tissue injury [34, 35]. Other factors would be hypothermia and acidosis, affecting the coagulation cascade and the consumption of coagulation factors by itself [33].

Coagulopathy was first observed in patients with severe traumatic injuries independent of the resuscitation process with a six-fold mortality rate increase [36–39]. Researchers found an endothelial membrane, later defined as the glycocalyx, noted to have an important role in endothelial permeability maintenance and suggested that during transfusion of plasma in the hemorrhagic shock population, glycocalyx preservation is greater than when compared with resuscitation with other fluids [40]. In severely traumatized individuals, coagulopathy has a multifactorial mechanism. However, it is now understood that innumerable molecules and cellular mediators integrate this complex mechanism from the moment of trauma, even before the volume loss is observed [41]. Due to this evidence, military surgeons started again to use the concept of whole blood used in past wars but now gathering packed red blood cells (PRBC), fresh frozen plasma (FFP) and platelets (PLT) into their transfusion protocols. Results from this experience in the wars of Iraq and Afghanistan showed that patients receiving
a high ratio of FFP related to the number of PRBCs had a lower mortality rate when compared to those protocols that used less FFP [42]. The result of this study was widely reproduced in the civilian field, for blunt and penetrating trauma mechanisms in a ratio of 1 : 1 : 1 [42–47].

The promising results of the use of a balanced resuscitation with plasma have been attributed to the reduction of inflammation, edema and vascular permeability by repairing the tight junctions of the vascular endothelium and the glyocalyx layer, besides preserving the platelet function and clot formation [48–50]. The use of plasma also reduces blood hypercoagulability by modulating the generation of thrombin [51].

A limiting factor in the use of FFP is the preparation time: 45 minutes before starting the transfusion. In 2009, a study that evaluated the transfusion time of each blood component found a bias in retrospective studies that supported the use of balanced resuscitation. The time of the first transfusion of FFP was significantly longer than PRBC, 93 minutes versus 18 minutes respectively, so patients did not survive until transfused with plasma, generating therefore a survival bias [52].

A prospective study done to overcome this impasse showed that although the use of plasma resuscitation did not improve survival within 24 hours, there were fewer deaths due to exsanguination in this group of patients and up to three hours mortality decrease. There was no difference in complications between the groups with balanced resuscitation with plasma when compared to those with use of PRBC alone [53–56]. New studies discuss the benefit of early plasma use in the prehospital setting, pointing to a 30-day mortality reduction in those patients with a high risk of severe hemorrhagic shock who received plasma in aeromedical transport before hospital admission [57]. However, another study evaluating the use of plasma in ground transport did not show mortality rate reduction for short transports [58].

The use of whole blood as an option for transfusion of severely traumatized patients came back in the conflicts of the Middle East, a practice abandoned since the 1970s [59, 60]. Patients who received whole blood, compared to those who received a balanced volume resuscitation with plasma, achieved greater survival in 24 hours and 30 days [61–64]. Some differences between whole blood and balanced resuscitation with plasma are shown in Table 1 [65, 66].

As a result of changes in the scientific evidence regarding resuscitation of the traumatized patient, a restriction was made on the use of crystalloid fluids. In animal models, mean systolic blood pressure values of 94 mm Hg and mean arterial pressure of 64 mm Hg were those reported as limits for maintenance of hemostasis [67–70]. This concept was known as permissive hypotension or hypotensive resuscitation.

Ironically, there was a pendulum movement in the history of trauma patients’ resuscitation management. However, it is necessary to emphasize that current management is based on solid evidence with greater understanding of the involved pathophysiological mechanisms. Also, development of new technologies in the diagnosis of coagulopathy, such as thromboelastography (TEG) for instance, have to date an important role in the management of severe bleeding and coagulopathy, helping healthcare providers in the decision-making process.

TEG was developed 70 years ago to evaluate thrombus initiation, formation, strength, stability and consumption in hyper/hypo coagulation patients [71–74]. Through TEG it is possible to visualize the whole coagulation cascade in real time instead of just the plasma, allowing accurate diagnosis of coagulation factor deficiency or its dilution, hyperfibrinolysis and platelet dysfunction [71, 72].

**BLEEDING CONTROL IN THE PRE-HOSPITAL SETTING – CURRENT STATUS AND FUTURE POSSIBILITIES**

Bleeding following severe trauma remains the potentially most preventable cause of death that typically occurs within the first three hours after injury. To improve outcomes we should consider a “care set” that includes measures to facilitate early diagnosis, rapid bleeding control, local and systemic hemostatic support, and reduction of the time spent at the scene [75]. In the last decade a paradigm shift has been witnessed regarding treatment strategies and transfusion algorithms [76], with emphasis on hemostatic resuscitation and damage control. The key objective of this proactive and empirical approach to transfusion is to focus directly on acute coagulopathy subsequent to traumatic injury, which in turn is associated with a fourfold increase in mortality and unfavorable patient outcomes.

**TABLE 1. Essential differences between transfusion with whole blood and 1 : 1 : 1 ratio**

<table>
<thead>
<tr>
<th>Blood Component</th>
<th>Whole Blood (500 mL)</th>
<th>Plasma (660 mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hematocrit</td>
<td>↑ 38% to 50%</td>
<td>↑ 29%</td>
</tr>
<tr>
<td>Platelets (UL/ML)</td>
<td>150.000 to 400.000</td>
<td>88.000</td>
</tr>
<tr>
<td>Coagulation factors</td>
<td>100% activity</td>
<td>65% activity</td>
</tr>
<tr>
<td>Others</td>
<td>–</td>
<td>Presence of anticoagulants</td>
</tr>
</tbody>
</table>
Identification of the bleeding source should be performed as part of the initial evaluation at the scene. Good clinical insight and a high suspicion rate remain important diagnostic tools. Points of care coagulation measurements, for instance, are of limited value in patients with significant bleeding. In the same way, prehospital use of ultrasonography, for diagnostic purposes only, remains in discussion. Critics argue that it adds little additional information and may delay the transfer to the hospital for definitive control of bleeding.

Undoubtedly the immediate priority is to locate any external bleeding sites and provide direct control. The recently published Hartford Consensus, Chapters I-IV, of the American College of Surgeons also suggests new evidence-based methods to stop the bleeding [77]. Foley catheters inserted in the path of the penetrating wound, for example, inflated and subsequently retracted to the edge of the skin, are good adjuncts for junctional injuries and neck wounds. Topical hemostatic dressings help in clot formation and can be applied to cavities where bleeding is difficult to directly control.

The use of topic hemostatic agents is an old concept, used in different ways by ancient civilizations. The Egyptians made use of a mixture of wax, grease, and barley in an effort to stop the bleeding. In ancient Greece, priests and healers of the time used hemostatic herbs on traumatic wounds. Recently, advances in biotechnology have resulted in the development of topical hemostatic agents that are currently available for pre-hospital use. Such agents range from absorbable topical hemostats, such as gelatins, collagen and regenerated oxidized cellulose to biologically active topical hemostats such as thrombin, biological sealants or other agents combined.

The use of tourniquets in limbs is now well established in pre-hospital care and has already been shown as a life-saving measure, particularly when applied before the onset of hemorrhagic shock. Complications such as nerve damage are rare when tourniquets are properly applied. The Eastern Association for the Surgery of Trauma recently published guidelines recommending its use in the civilian setting as a measure of interruption of severe bleeding in cases of penetrating lower limb injuries [78].

Radical interventions to control life-threatening bleeding include pre-hospital thoracotomy for aortic cross-clamping and the use of the Resuscitative Endovascular Balloon for the Occlusion of the Aorta (REBOA) for larger bleeding of the trunk and pelvis. Pre-hospital thoracotomy for penetrating trauma is an established intervention in a physician-led emergency system and is associated with 18% survival rates in selected patient groups. However, all efforts should be focused on rapid transit to the hospital in order to obtain definitive surgical treatment. Relief of tamponade with cardiac injury control is still the primary goal for pre-hospital thoracotomy. REBOA has been used successfully in emergency rooms with or without fluoroscopy support, in any retroperitoneal zones (I, II or III). REBOA has already been used in the war field and has become promising for use in the pre-hospital environment [77–80]. Indeed, REBOA may play an important role in the pre-hospital management of severe pelvic injuries, with the balloon at the level of the aortic bifurcation, aiding in the control of catastrophic pelvic bleeding [79, 80]. Globally, both REBOA and transfusion of blood products in an out-of-hospital environment are not yet usual.

Direct control of bleeding should be accompanied by hemostatic resuscitation and damage control surgery when indicated. The efficacy of therapy with high doses of blood components and the ideal plasma ratio is divergent. The PROPPR study was the first randomized controlled clinical trial that proposed investigating ratios of blood products in trauma [81].

Hemostasis is dependent on fibrinogen as a substrate for clot formation. Fibrinogen levels decrease rapidly and significantly during massive bleeding, a fact associated with increased mortality, and its early supplementation (cryoprecipitate) has been shown to improve patient survival [82]. Early and high dose fibrinogen replacement is the subject of three randomized trials in the United Kingdom (CRYOSTAT – ED and E-FIT 1) and Austria (FITIC – pre-hospital). The fibrinogen concentrate has the potential to be the main pro-coagulant agent for pre-hospital hemostatic resuscitation. E-FIT 1 specifically demonstrates that the early use of fibrinogen is feasible in trauma, but larger randomized clinical trials are needed to determine its results in reducing mortality [83]. All patients with severe bleeding have a profound activation of the fibrinolytic system [84]. The CRASH-2 study showed clear benefits of reducing mortality when using early tranexamic acid (TXA) in hemorrhagic shock following trauma. Its use should be considered in all patients with hemorrhagic shock less than 3 hours after the traumatic event [85].

Again, effective treatment of pre-hospital bleeding depends on rapid identification of bleeding, direct control, hemostatic resuscitation, and rapid transfer to a trauma center.

**DAMAGE CONTROL RESUSCITATION IN THE PRE-HOSPITAL SETTING**

The high prevalence and impact of coagulopathy in trauma victims requires a strategy of proac-
tive emergency room action that should include administration of PRBC, FFP, platelets and tranexamic acid [86]. Damage control resuscitation (DCR) provides transfusions with plasma and platelets, as well as PRBC in an immediate and sustained manner, as part of the massive transfusion protocol for patients with severe life-threatening bleeding. Rapid and proactive treatment of trauma-associated coagulopathy is now recognized as essential for reducing mortality. Although the early and effective reversal of coagulopathy is well documented, its prevention in massive transfusion remains under discussion, and randomized controlled trials are still scarce.

MASSIVE TRANSFUSION PROTOCOL

Patients with severe life-threatening bleeding require massive transfusion protocol (MTP) activation. There are several definitions of massive transfusion ranging from 10 to 20 units of PRBCs in 24 hours, or the use of 50 units of blood components in 24 hours. From a practical point of view, transfusion requirement of > 4 PRBC in 1 hour, or blood loss > 150 mL min⁻¹ with hemodynamic instability and ABC score > 1, is a reasonable indication for MTP. ABC score is shown to have sensitivity of 75% and specificity of 85% [86].

RECOMBINANT FACTOR VIIa

The use of recombinant factor VIIa in trauma has complemented the therapeutic armamentarium in the treatment of trauma-associated coagulopathy (ACoTS). Recombinant activated factor VII (rFVIIa) is a hemostatic agent originally developed for the treatment of hemophilia, factor VII deficiency, Glanzmann’s thrombocytopenia and patients refractory to platelet transfusion. Activation of platelets at the lesion site is the reason for the localized action of rFVIIa, since it causes clotting at the site of bleeding. Controlled and randomized prospective trials with different doses of rFVIIa are required to explore the potential efficacy of lower doses in ACoTS to reduce costs and adverse effects such as thromboembolic complications. The efficacy and safety of rFVIIa as adjunctive therapy for the control of patients with severe blunt and penetrating trauma were evaluated in a randomized, double-blind, placebo-controlled study. The authors compared three doses of rFVIIa (doses of 200, 100, and 100 g kg⁻¹) with three placebo doses in addition to standard treatment for patients who received 6 PRBC units within a 4-h period. In 143 traumatized patients, PRBC transfusion was significantly reduced with rFVIIa compared to placebo, and the need for massive transfusion (20 PRBC units) was reduced (14% vs. 33%, respectively). In penetrating trauma (134 patients), there was no reduction in mortality.

Adverse events, including thromboembolic events (a total of 12, six in each group) were equally distributed between the groups. The authors concluded that rFVIIa is safe within the dose investigated and may be a promising adjuvant for existing trauma therapy. The effects of liberal administration of rFVIIa in trauma patients with bleeding are unknown because their procoagulant effect must be balanced against a real risk of thromboembolic events [59].

FIBRINOGEN AND CRYOPRECIPITATE

Fibrinogen deficiency develops earlier than other coagulation factors. Fibrinogen is therefore an obvious target for the replacement of cryoprecipitate containing fibrinogen, factor VIII, factor XIII, and von Willebrand factor or fibrinogen concentrate. Updated guidelines recommend the use of one of the two products if plasma fibrinogen levels fall below 1.0 g L⁻¹. Concerns about patient exposure to a large number of donors and the associated risk of viral transmission limit the use of cryoprecipitate to situations where conventional treatment has failed [83].

TRANEXAMIC ACID

Fibrinolysis is a normal response to surgery and trauma in order to maintain vascular permeability and may become exaggerated (hyperfibrinolysis) in some cases. Tranexamic acid (TXA) is an antifibrinolytic drug, analogous to lysine, and interferes with the binding of fibrin to plasminogen, which is required for the activation of plasmin. Anti-fibrinolytic drugs can prevent breakage of the clot and thereby reduce blood loss in trauma. The results of the CRASH-2 study showed that early treatment with tranexamic acid is more effective in reducing the risk of death from bleeding. Patients who received tranexamic acid within 1 hour of injury had a lower bleeding-related mortality rate (5.3% vs. 7.7% for placebo). Similarly, patients who received treatment within 1-3 hours after injury also had a significantly lower risk of death from bleeding. However, patients who received TXA with more than 3 hours of injury had an increased risk of death compared to placebo, 4.4% vs. 3.1%, respectively. The current recommendations for the use of TXA are as follows: 1) TXA should be routinely used in patients with trauma, with evidence of bleeding, 2) TXA should be included in the MTP, 3) TXA should be given within 3 hours of injury, 4) administer 1 g of TXA intravenously, followed by infusion of 1 g over 8 hours [83–86].

CALCIUM ADMINISTRATION

Ionized hypocalcemia is common in the critically ill and associated with increased mortality. Calcium is an important cofactor for many components of the coagulation cascade. Citrate, used as an antico-
agulant in many of the prepared components for transfusion, causes calcium depletion and exacerbates hypocalcemia. The dose-response effect of hypocalcemia on coagulation is difficult to measure. A recent non-systematic review has shown that calcium concentrations less than 0.6–0.7 mmol L\(^{-1}\) could lead to significant coagulation changes and recommended keeping the concentration level of at least 0.9 mmol L\(^{-1}\) [63].

**AGED PRBC**

Red cell transfusion with high storage time has been associated with increased rates of infectious complications and multiple organ failure. Although the lifespan of erythrocyte units is about six weeks, the adverse effects of administration (believed to be leukocyte-mediated) have been shown to be frequent after two weeks of storage. When blood is stored, the level of antioxidants decreases, resulting in oxidative damage that converts hemoglobin to methemoglobin, which cannot bind to oxygen. If blood is stored for more than 7 days, it loses 2,3-DPG by shifting the oxygen-hemoglobin dissociation curve to the left, thereby decreasing the amount of oxygen to the tissues. Storage also promotes hemolysis and acidosis. Researchers have shown that transfused blood is an independent predictor of multiple organ failure and death. A large retrospective cohort study of patients with recent trauma showed that transfusion of red cells stored for more than two weeks was associated with a significant increase in the chance of death. This finding was observed despite the leucoreduction, but it was evident only among the patients who received at least six units of packed red blood cells. Recently donated red cells are therefore preferable to trauma victims requiring massive transfusion, although such practice has obvious logistical and resource implications [55, 56, 60, 63].

**STOPPING THE BLEEDING IN THE PRE-HOSPITAL SETTING: DECISION-MAKING AND CRITICAL DECISION**

Bleeding is responsible for a large number of trauma deaths in the prehospital setting before and after the arrival of the emergency medical service at the scene. Although it is impossible to correlate the prognosis with exact amounts of blood loss, it has certainly been well demonstrated that as blood loss increases, so does the incidence of death. In order to prevent greater lethality of patients rescued in an austere or pre-hospital setting, it is essential that the rescue team is focused on preventing or fighting the lethal triad consisting of hypotension, acidosis and hypothermia. This set of factors is strongly associated with multiple organ failure and subsequent death when not readily reversed. The need for perception, control, and correction of hemorrhage and the lethal triad is as important as the recognition and obtaining of a safe airway.

All approaches to controlling external hemorrhage have their pros and cons. Each modality has its risks and benefits, advantages and disadvantages when compared to the following, and none of them should be considered as a “gold standard” in the control or bleeding management. Each case may be suitable for use of any particular device, modality or approach. It is very important to stress that ensuring a safe airway and cervical spine protection, effective ventilation and hemorrhage control is the basis of any life-sustaining measure, as well as the prevention of the lethal triad.

Practice of constant training and simulations enhances the life-saving physician’s ability to make critical decisions as it exposes one to different scenarios with repetition and debriefing. It is also in these simulation scenarios, with adequate training, that the ability to stagger bleeding interruption measures becomes clearer. For example, in the failure of wound compression effectiveness as a measure of bleeding discontinuation, limb elevation, proximal artery compression, or tourniquet use should be employed. It is neither prudent nor correct to “wait a little longer” once the non-effectiveness of the hemorrhage control has been established. The medical team should not miss precious seconds trying to decide whether a tourniquet is needed. Digital pressure should be applied directly to the bleeding source and held for 3-5 minutes. Bleeding should stop immediately. Commercial devices that apply pressure to the wound while maintaining direct and uninterrupted compression of the bleeding can be extremely helpful [87]. The application of the tourniquet should be about three centimeters proximal to the wound by adjusting it until the bleeding stops. For most extremity bleeding, this treatment is safe and effective [88]. For wounds on the proximal ends, mutilated extremities, and especially junctional wounds (e.g., groin, armpit, shoulder and neck), tourniquets may not be applicable. CRoC (Combat Ready Clamp) type tourniquet, JETT (Junctional Emergency Tourniquet Tool) or ITClamp (a device for temporary interruption of hemorrhage in places of difficult compression), are rising options [88, 89]. Immobilization is also very useful in the prehospital setting. Immobilization of the extremity helps maintain anatomical position and natural blood flow. In the case of a lacerated radial artery, for instance, direct external compression, maintenance of the natural position of the wrist keeps the flow of the ulnar artery ensuring that the site of the injury is not under more pressure than it normally would be. Immobilization can also help prevent the dislodgment of a formed clot. For pelvic and femoral fractures, bleeding is al-
ways a significant concern. Figure 1 represents a proposed flow chart for hemorrhage control.

OTHER PERSPECTIVES FOR THE FUTURE

There are some new therapies that are appearing to be of great promise.

Self-expanding polymer foams/sponges are an interesting option. When packaged in a wound, these products are able to absorb 30 times their weight in water, while expanding many times their size [89]. These actions serve two purposes: 1) expansion provides compression and force similar to tamponade at the bleeding site; and 2) by absorbing water from the source of bleeding, they concentrate the blood products naturally used by the body for coagulation. It is promising as a form of hemostasis to control damage to open thoracic organs and abdominal trauma (penetrating wounds) [90]. Another new therapy with perhaps the greatest potential for severe and massive bleeding control is a group of products known as procoagulant supplements [90]. Such dressings are impregnated with highly concentrated human coagulation factors and calcium, surpassing most other hemostatic agents in the immediate cessation of bleeding and in promoting wound coagulation. Containing biologically active compounds derived from coagulation, they are estimated to have an almost 100-fold increase in cost compared to other current products.

CONCLUSIONS

The implementation of measures to stop acute bleeding in the pre-hospital setting is a well-known and well-founded measure. However, the current evidence demonstrates that these measures go far beyond compression and elevation of the limb, as was known in the past. A deep understanding of the mechanism of coagulopathy and a new adjuvant arsenal to control bleeding are essential for a better quality of pre-hospital medical care as well as lower mortality rates.


